Results 221 to 230 of about 93,200 (346)

Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Fabià Torres‐Betato, Lluís Puig
wiley   +1 more source

Building the foundations for an international patient‐centred outcomes set for psoriasis: A scoping study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This scoping study refined the first patient‐centred outcome set for psoriasis, involving patient representatives and dermatologists from 22 countries. The proposal includes 18 patient‐relevant outcomes, 2 patient experiences, corresponding outcome measurement instruments and 50 case‐mix variables.
Emma Vyvey, Rani Soenen, Hazel H. Oon, Sicily Mburu, Maren Awici‐Rasmussen, Azura Mohd Affandi, Wayne Gulliver, Siew Eng Choon, Tiago Torres, Allison FitzGerald, Alvaro Gonzalez‐Cantero, Anna López‐Ferrer, Chih‐Hung Lee, Fernando Valenzuela, Julia‐Tatjana Maul, Luis Puig, Masanori Okuse, Mohamed EL‐Komy, Peter Foley, Ron Vender, Wolf‐Henning Boehncke, Josef Pohunek, Ya Hsin Wang, Angela Londoño‐García, Gail Todd, Margarita Velasquez‐Lopera, Mark Lebwohl, Edmund Lau, Marcus Schmitt‐Egenolf, Niels Hilhorst, Spencer Connell, Elfie Deprez, Nanja van Geel, Christopher Griffiths, Peter Van de Kerkhof, Jo Lambert   +35 more
wiley   +1 more source

Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study. [PDF]

Sci Rep
Gentileschi S, Terribili R, Gaggiano C, Fiorentini E, Cometi L, Cigolini C, Perrotta FM, Scriffignano S, Di Cato L, Panaccione A, Niccoli L, Cantini F, Benucci M, Li Gobbi F, Delle Sedie A, Vitale A, Lubrano E, Frediani B, Guiducci S.   +18 more
europepmc   +1 more source

Angiogenic and Inflammatory Properties of Psoriatic Arthritis [PDF]

, 2013
Toshiyuki Yamamoto
openalex   +1 more source

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In Chinese patients with moderate to severe plaque psoriasis, bimekizumab treatment was well tolerated and led to significantly higher clinical response rates versus placebo, including complete skin clearance. These findings were consistent with global studies and suggest that bimekizumab is an effective treatment option for Chinese people living with ...
Lin Cai, Xiao‐Yong Man, Jinyan Wang, Aihua Wei, Ying Chen, Delphine Deherder, Jun Gao, Bengt Hoepken, Weiwei Sun, Tingting Lei, Jianzhong Zhang, the BE SHINING Study Group   +11 more
wiley   +1 more source

Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. [PDF]

Rheumatol Ther
Ogdie A, Middaugh N, Blachley T, Bourgeois T, Ling YL, Mundayat R, Fallon L, Masri KR, Mease PJ.   +8 more
europepmc   +1 more source

SAT0324 Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years' treatment [PDF]

, 2018
D. van der Heijde, Atul Deodhar, Oliver FitzGerald, Roy Fleischmann, Dafna D. Gladman, A.B. Gottlieb, Laura C. Coates, Bengt Hoepken, Lars Bauer, Luke Peterson, Majed Khraishi, Philip J. Mease   +11 more
openalex   +1 more source

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatologists worldwide reached consensus on criteria for dose reduction (DR) of biologics for psoriasis resulting in a DR algorithm for adalimumab, etanercept and ustekinumab. DR of IL‐17 and IL‐23 inhibitors was deemed feasible as well. This first international consensus provides essential information for uptake of biologic DR for psoriasis globally.
C. A. M. van Riel, W.‐H. Boehncke, J. L. W. Lambert, P. I. Spuls, L. S. van der Schoot, I. van Ee, E. M. G. J. de Jong, J. M. P. A. van den Reek, on behalf of the eDelphi consortium, M. Elkalioby, L. Fianen, L. Linhares Leite, C. Boesjes, S. Mahil, M. Franco, F. Valenzuela, C. Chaiyabutr, M. A. Lorna, F. Frez, O. Zargari, T. Hillary, H. Oon, L. Skov, M. Gupta, E. Sotiriou, N. Nguyen Loft, R. Ceovic, K. M. G. Klaassen, J. Wikström, C. Zachariae, P. Asawanonda, R. Vender, A. Carvalho, J. Song, C. Lan, J.‐T. Maul, D. Jullien, B. Hidalgo‐Matlock, A. Duvetorp, M. Gkini, D. Ioannidis, W. Veldkamp, J. Hugo, J. Barboza, A. Carugno, A. Londoño‐García, L. Schneller‐Pavelescu Apetrei, M. Ferran, F. Lafuente Urrez, N. Merino, M. Llamas Velasco, L. Puig, M. Bourcier, M. Perez Ferriols, T. Leonidze, D. Armijo, A. Eylenbosch, M. B. A. van Doorn, P. P. M. van Lumig, P. Ghislain, A. Nast, S. Lanssens, E. Sonkoly, D. J. Hijnen, E. M. Baerveldt, P. Gisondi, M. Tjioe, I. Haeck, K. Agerberg, Y. Okubo   +69 more
wiley   +1 more source

Presence of autoantibodies targeting the shared epitope in rheumatoid arthritis and psoriatic arthritis. [PDF]

Front Immunol
Graell E, Delgado JF, Domingo Gomez A, García-Marique M, Rusiñol M, Rodrigo A, Berenguer-Llergo A, Gratacos J, Calvet J.   +8 more
europepmc   +1 more source

Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis

Journal of Internal Medicine, EarlyView.
Abstract Objectives To investigate, in early rheumatoid arthritis, whether bridging with glucocorticoids (GCs) is associated with an increased risk of flare following GC tapering and withdrawal. Methods A total of 810 NOrdic Rheumatic Diseases Strategy Trials And Registries (NORD‐STAR) patients were included in this post hoc analysis: all received ...
Kristina Lend, Jos W. R. Twisk, Frieda A. Koopman, Anna Rudin, Merete Lund Hetland, Till Uhlig, Dan C. Nordström, Michael T. Nurmohamed, Bjorn Gudbjornsson, Kim Hørslev‐Petersen, Marte Schrumpf Heiberg, Tuulikki Sokka‐Isler, Gerdur Grondal, Espen A. Haavardsholm, Mikkel Østergaard, Jon Lampa, Ronald van Vollenhoven   +16 more
wiley   +1 more source